THRV-1268

DRUG3 trials

Sponsors

Thryv Therapeutics, Inc.

Conditions

Atrial FibrillationHeart FailureLong QT Syndrome (LQTS) 2

Phase 1

Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268

CompletedNCT06507839

Thryv Therapeutics, Inc.Atrial Fibrillation

Start: 2024-05-15End: 2024-11-01Updated: 2025-05-13

Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants

CompletedNCT07186946

Thryv Therapeutics, Inc.Heart Failure

Start: 2025-09-15End: 2025-10-20Updated: 2026-01-14

Phase 2

Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2)

RecruitingNCT07277582

Thryv Therapeutics, Inc.Long QT Syndrome (LQTS) 2

Start: 2026-03-07End: 2027-06-30Target: 64Updated: 2026-07-22